High expression of cystine–glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma

Autor: Christoph P. Beier, Helle Wohlleben, Bjarne Winther Kristensen, Sólborg Berglind Heimisdóttir, Casper Schau Mellegaard, Mia D. Sørensen, Mai Froberg Sørensen

Publikováno v: Sørensen, M F, Heimisdóttir, S B, Sørensen, M D, Mellegaard, C S, Wohlleben, H, Kristensen, B W & Beier, C P 2018, ' High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma ', Journal of Neuro-Oncology, vol. 138, no. 1, pp. 49–53 . https://doi.org/10.1007/s11060-018-2785-9

Epileptic seizures are an important cause of morbidity in glioma patients. Substantial lines of evidence support the concept of the excitatory neurotransmitter glutamate being a crucial mediator of glioma-associated seizures. In gliomas, non-vesicula

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4e6fc51c18081c34a3e24abd508921f
https://doi.org/10.1007/s11060-018-2785-9

Identification of novel cystinuria mutations and polymorphisms in SLC3A1 and SLC7A9 genes: absence of SLC7A10 gene mutations in cystinuric patients

Autor: Anthoula Chatzikyriakidou, Nikolaos Sofikitis, Ioannis Georgiou

Cystinuria represents 3% of nephrolithiasis in humans with an overall prevalence of 1 in 7,000 neonates. Two genes have been reported to account for the genetic basis of cystinuria, the SLC3A1 and the SLC7A9. Recently, the possible involvement of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ceee29af70e4f2b6496f10a800a4e7d
http://olympias.lib.uoi.gr/jspui/handle/123456789/21052